Retatrutide, from Soma Chems , is gaining increasing attention as a potential therapy for metabolic regulation. This innovative medication integrates the properties of a GLP-1 receptor stimulant and a GIP receptor agonist , aiming to not only promote metabolic improvements but also target associated metabolic issues . Initial patient studies have s